Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEMOBLOC: PVB vs TEB in Esophageal Surgery
NCT03185403Completed
- Sponsor
- CHU de Lille
- Start
- Dec 2013
- Primary completion
- Jul 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of ropivacaine and sufentanil in esophageal cancer (2 arms), sponsored by CHU de Lille. Primary endpoint: Frequency of hypotension episodes at 24 hours. Started Dec 2013; status: completed.
02
Drugs
ropivacainesufentanil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03185403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185403.